FREDERICK, Md., March 8 /PRNewswire-FirstCall/ -- BioElectronics Corporation, announced today that it is introducing its improved foot and ankle products.
BioElectronics Corp. CEO Andrew J. Whelan commented, “We have taken proven pulsed electromagnetic therapy down to a small microchip and embedded it into an affordable, soft, conformable, easy to apply foam patch for the treatment of inflammatory foot and ankle conditions. Lighter, thinner, and easier to affix, ActiPatch is a major leap forward in podiatric medicine. The new medium (8.1 cm X 5.8 cm) and large (8.9 cm X 8.9 cm) rectangular patches provide significant flexibility for treatment whether embedded in a brace or simply wrapped for extended convenient therapy. We will be initiating Canadian and European sales during the second quarter. We have also begun the process for multiple Investigational Review Board approvals for clinical trials to obtain additional US FDA market clearances.
About BioElectronics:
BioElectronics Corporation is a developer and marketer of advanced, inexpensive, disposable, drug-free, medical devices cleared by the US FDA, the European Union and the Canadian regulatory authorities. ActiPatch(R) Therapy is a dermal patch with an embedded battery operated microchip that delivers weeks of continuous pulsed therapy for a few dollars a day. The patch delivery system and the Company’s patented technology provides an inexpensive, self- administered equivalent of the operator-administered pulsed electromagnetic energy therapy used extensively world-wide to reduce swelling, relieve pain and enhance the healing of post-surgical incisions, chronic wounds (bedsores) and orthopedic conditions.
For more information visit http://www.bioelectronicscorp.com
Safe Harbor Statement:
This news release contains forward-looking statements related to future growth and earnings opportunities. Such statements are based upon certain assumptions and assessments made by management of both companies in light of current conditions, expected future developments and other factors it believes to be appropriate. Actual results may differ as a result of factors over which the companies have no control.
BioElectronics Corporation
CONTACT: Andrew J. Whelan, President & CEO, or Thomas O’Connor, EVPOperations & COO, +1-301-644-3906, or +1-301-644-3939 (fax), orinfo@bioelectronicscorp.com, both of BioElectronics Corporation
Web site: http://www.bioelectronicscorp.com//
